Serina Therapeutics appoints Dr. Simba Gill as Executive Chairman

Serina Therapeutics, Inc.

Dr. Simba Gill appointed Executive Chairman effective April 12, 2024.
Annual cash fee of $300,000 and grant of 295,300 stock options under 2024 Equity Incentive Plan.
Dr. Gill has over 35 years of biotech leadership including Maxygen, Systemix, Boehringer Mannheim, Celltech.
Five-year post-termination non-compete and non-solicitation covenants apply.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simba Gill

Executive Chairman

SER · Serina Therapeutics, Inc.

Effective: 2024-04-12
Filed: April 17, 2024, 7:59 PM ET

On April 17, 2024, Serina Therapeutics, Inc. (the “Company”) announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective as of April 12, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simba Gill was appointed as Executive Chairman at Serina Therapeutics, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On April 17, 2024, Serina Therapeutics, Inc. (the “Company”) announced the appointment of Simba Gill, Ph.D., as the Company’s Chairman of the Board of Directors, effective as of April 12, 2024.

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-015037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.